On Tuesday, the Senate Health, Education, Labor and Pensions (HELP) Committee held the first of three planned hearings on drug pricing. Lamar Alexander (R-Ky.), the committee’s chair, characterized the hearings as a bipartisan fact-finding exercise. He did not suggest that they will lead to legislation.
Separately, the Trump administration continues to assemble plans to address drug pricing. Members of BIO’s board of directors met with HHS Secretary Tom Price on Monday to make the industry’s case for pro-innovation policies.
The White House is drafting an Executive Order on drug pricing. The order will instruct executive agencies to use value-based contracts for drug purchases, and to pursue trade policies that enhance the intellectual property rights of American pharmaceutical companies, according to individuals familiar with the Trump administration’s planning.
Read Full Article Here >>